GlycoT and Genovis cross-licensing agreements
JUNE 6, 2021
GlycoT and Genovis enter into cross-licensing agreements on novel antibody conjugation technology. Under the agreement, Gneovis ( a Sweden publicly traded company) will use the GlycoT’s transglycosylation technology to develop research and diagnostic products. Genovis has launched first glycan remodeling kit (TransGLYCIT®) incorporating GlcyoT’s technology on June 23, 2021. Meanwhile, GlycoT expands its freedom of operation for the development of antibody-based therapeutic by licensing Genovis’s deglycosylation technology.
Read the full article at: www.glycot.com
